Glenmark Pharmaceuticals Ltd Share Price
(GLENMARK)
₹1342.4
as on 04:01PM, 17 Apr 2025
Glenmark Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹1,336Day's Price Range₹1,376.852 Week's Low
52 Week's High
₹985.252-Week Price Range₹1,830.95
| Returns % | |
| 1 Month Return | -7.82 % |
| 3 Month Return | -10.72 % |
| 1 Year Return | + 28.85 % |
| Market Stats | |
| Previous Close | ₹1,356.80 |
| Open | ₹1,368.20 |
| Volume | 6.13L |
| Upper Circuit | ₹1,492.40 |
| Lower Circuit | ₹1,221.20 |
| Market Cap | ₹37,880.94Cr |
Glenmark Pharmaceuticals Ltd Fundamentals
P/E Ratio
-215.47
PEG Ratio
-11.35
Market Cap
₹37,880.94 Cr
P/B Ratio
1.18
EPS
-50.8
Dividend Yield
0.26
Sector
Pharmaceuticals
ROE
6.98
Mutual Fund Holdings of Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd Analyst Rating
based on 13 analysts
69.23%
Buy
23.08%
Hold
7.69%
Sell
Based on 13 analysts offering long term price targets for Glenmark Pharmaceuticals Ltd. An average target of ₹1687.38
Source: S&P Global Market Intelligence
Glenmark Pharmaceuticals Ltd Share analysis
Glenmark Pharmaceuticals Ltd price forecast by 13 analysts
Upside of25.70%
High
₹2032
Target
₹1687.38
Low
₹1265
Glenmark Pharmaceuticals Ltd target price ₹1687.38, a slight upside of 25.7% compared to current price of ₹1342.4. According to 13 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glenmark Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2027:42.40%
Forecast
Actual
Including amortisation and stock based compensations
Glenmark Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Announces Adderall Launch Plans - 17 Apr, 2025
Glenmark Pharmaceuticals is set to launch a generic version of Adderall in May 2025, targeting a significant ADHD market. The stock saw increased trading volume despite a slight price decline.Glenmark Launches New Products Amid Trading Surge - 16 Apr, 2025
Glenmark Pharmaceuticals Inc. plans to launch Dextroamphetamine products in May 2025 to alleviate U.S. shortages. Meanwhile, Glenmark's stock experiences a significant trading volume increase but declines in price.Glenmark Faces Stock Decline Amid USFDA Recall - 09 Apr, 2025
Glenmark Pharmaceuticals faced significant stock declines after the USFDA announced a Class-II recall of 39 drugs due to manufacturing issues, leading to a 7% drop in shares.Glenmark Appoints New President Amid Market Decline - 07 Apr, 2025
On April 7, 2025, Glenmark Pharmaceuticals appointed Anurag Mantri as President. The stock faced pressure as Indian pharma shares dropped due to US tariff comments.Glenmark Shares Drop Amid Tariff Concerns - 04 Apr, 2025
Glenmark Pharmaceuticals shares fell 4.35% to ₹1,478.00 following President Trump's warning of potential pharmaceutical tariffs, reversing previous gains. Analysts express cautious optimism despite challenges.Glenmark Pharma Shares Surge on Tariff Exemption - 03 Apr, 2025
Glenmark Pharmaceuticals' shares increased by 3.28% following the U.S. government's exemption of pharmaceuticals from a newly imposed 26% reciprocal tariff, providing relief to Indian drug manufacturers.Glenmark Launches Vancomycin Injection in US Market - 01 Apr, 2025
Glenmark Pharmaceuticals Inc. has launched Vancomycin Hydrochloride for Injection USP in various dosages, targeting a significant market opportunity worth approximately $39.3 million.CDSCO Flags Spurious Batch of Telma H Drug - 30 Mar, 2025
The CDSCO has flagged a spurious batch of Telma H, a hypertension medication manufactured by Glenmark Pharmaceuticals, along with 103 other drugs failing quality tests. The actual manufacturer confirmed the flagged batch was not produced by them.Glenmark to Close Swiss Manufacturing Facility - 29 Mar, 2025
Glenmark Pharmaceuticals announced the closure of its Switzerland-based IGI facility by July 2025. The move aims to enhance its clinical pipeline by transitioning manufacturing to established CDMOs, with no adverse impact on financials expected.HSBC Upgrades Glenmark to 'Buy' with 22% Upside - 28 Mar, 2025
HSBC has upgraded Glenmark Pharmaceuticals to a 'Buy' rating, raising the target price to ₹1,785, citing potential from ISB 2001 and margin expansion. The company is in advanced talks for out-licensing ISB 2001, which could significantly boost sales. Glenmark's core business is also expected to benefit from reduced R&D costs and new product launches, positioning it for a potential re-rating.Glenmark Pharmaceuticals Gains Nifty Inclusion and Licensing Deal - 26 Mar, 2025
Glenmark Pharmaceuticals has entered a licensing agreement for the oncology drug KN035 and will be added to the Nifty Midcap 150 index. Shares saw fluctuations, reaching an intraday high of Rs 1,489.75.Glenmark Receives FDA Approval for Allergy Eye Drops - 20 Mar, 2025
Glenmark Pharmaceuticals has received FDA approval for its Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, an OTC allergy eye drop. This product is bioequivalent to Pataday® and will enhance Glenmark's OTC ophthalmic portfolio in the U.S., addressing market needs and reinforcing its commitment to quality healthcare solutions.
Insights on Glenmark Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 23.05% to 23.51% in Dec 2024 quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, GLENMARK has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 11.41% to 12.12% in Dec 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 46.65% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 55.1% return, outperforming this stock by 24.9%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 3.47K Cr → 3.41K Cr (in ₹), with an average decrease of 1.6% per quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 17.06% to 15.96% in Dec 2024 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 354.21 Cr → 347.96 Cr (in ₹), with an average decrease of 1.8% per quarter
- NEGATIVE IMPACT
Price Dip
In the last 7 days, GLENMARK stock has moved down by -1.6%
Glenmark Pharmaceuticals Ltd Financials
Glenmark Pharmaceuticals Ltd Index Inclusions
Glenmark Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.65% | 0.00 | |
| Foreign Institutions | 23.51% | 1.99 | |
| Mutual Funds | 12.12% | 6.20 | |
| Retail Investors | 15.96% | ||
| Others | 1.77% |
Glenmark Pharmaceuticals Ltd Key Indicators
Glenmark Pharmaceuticals Ltd Valuation
Glenmark Pharmaceuticals Ltd in the last 5 years
Lowest (-275.05x)
December 28, 2023
Today (-215.47x)
April 17, 2025
Industry (53.02x)
April 17, 2025
Highest (95.94x)
September 14, 2023
Glenmark Pharmaceuticals Ltd Earnings and Dividends
Glenmark Pharmaceuticals Ltd Earnings Results
Glenmark Pharmaceuticals Ltd’s net profit jumped 199.03% since last year same period to ₹347.96Cr in the Q3 2024-2025. On a quarterly growth basis, Glenmark Pharmaceuticals Ltd has generated -1.76% fall in its net profits since last 3-months.
Read More about Earnings ResultsGlenmark Pharmaceuticals Ltd Dividends May,2024
In the quarter ending March 2024, Glenmark Pharmaceuticals Ltd has declared dividend of ₹2.50 - translating a dividend yield of 0.19%.
Read More about Dividends
Glenmark Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Glenmark Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
Glenmark Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹37,880.94 Cr | 65.49% | 0.52 | -₹1,434 Cr | ₹11,813 Cr | |
| BUY | ₹29,735.73 Cr | 143.09% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹14,638.87 Cr | 43.16% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹4,865.55 Cr | 1.9% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹15,265.25 Cr | 46.78% | 0.68 | ₹218 Cr | ₹1,296 Cr |
About Glenmark Pharmaceuticals Ltd
Revenue: ₹3,301.90Cr as on December 2024 (Q4 24)
Net Profit: ₹348.03Cr as on December 2024 (Q4 24)
Listing date: 07 Feb, 2000
Chairperson Name: Glenn Saldanha
| Organisation | Glenmark Pharmaceuticals Ltd |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Glenmark Pharmaceuticals Ltd
What is Glenmark Pharmaceuticals Ltd price today?
Glenmark Pharmaceuticals Ltd share price today stands at ₹1342.4, Open: ₹1368.2, Previous Close: ₹1356.8, High: ₹1376.8, Low: ₹1336, 52 Week High: ₹1830.95, 52 Week Low: ₹985.2.
How to Buy Glenmark Pharmaceuticals Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Glenmark Pharmaceuticals Ltd shares
What are today's traded volumes of Glenmark Pharmaceuticals Ltd?
Today's traded volume of Glenmark Pharmaceuticals Ltd(GLENMARK) is 6.13L.
What is today's market capitalisation of Glenmark Pharmaceuticals Ltd?
Today's market capitalisation of Glenmark Pharmaceuticals Ltd(GLENMARK) is ₹37880.94Cr.
What is the 52 Week High and Low Range of Glenmark Pharmaceuticals Ltd?
How much percentage Glenmark Pharmaceuticals Ltd is down from its 52 Week High?
Glenmark Pharmaceuticals Ltd (GLENMARK) share price is ₹1342.4. It is down -26.68% from its 52 Week High price of ₹1830.95
How much percentage Glenmark Pharmaceuticals Ltd is up from its 52 Week low?
Glenmark Pharmaceuticals Ltd (GLENMARK) share price is ₹1342.4. It is up 36.26% from its 52 Week Low price of ₹985.2